Changes on the Horizon with Novel Oral Therapies for Musculoskeletal Indications
This research service covers the therapeutics for rheumatic diseases market in
the United States from 2009 to 2017, with 2011 as the base year. The focus of
this research is on biologics and other treatments prescribed as add-on
therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and
ankylosing spondylitis (AS); background standard of care therapies are not
covered in this study. Included in the study are products already on the
market and products in development as well as patient and revenue forecasts.
Market challenges, drivers, and restraints are identified and assessed. The
market is segmented by disease indication: RA, PsA, and AS.
Key Questions This Study Will Answer
Is the market growing, how long will it continue to grow, and at what rate?
Is this a consolidated or diverse market? How will the structure evolve?
What are the unmet needs? How can emerging competitors meet these needs?
How will new agents fit into the treatment paradigm?
What are the major trends affecting the growth of this market? What are
the risks for participants or potential participants?
Table of Contents
Table of Contents
1. Rheumatic Diseases Therapeutics Market
Analysis of the United States Rheumatic Diseases Therapeutics Market
Executive Summary and Market Overview
2. Rheumatic Diseases Therapeutics Market - Total Market
Analysis of the Total Rheumatic Diseases Therapeutics Market
Drivers and Restraints
Forecasts and Trends
Demand Analysis
Market Share and Competitive Analysis
3. Rheumatoid Arthritis Segment
Analysis of the Rheumatoid Arthritis Segment
Segment Breakdown and Market Engineering Measurements
Patient Forecast
Pricing Trends and Forecast
Revenue Forecast
Market Share Analysis
4. Psoriatic Arthritis Segment
Analysis of the Psoriatic Arthritis Segment
Segment Breakdown and Market Engineering Measurements
Patient Forecast
Pricing Trends and Forecast
Revenue Forecast
Market Share Analysis
5. Ankylosing Spondylitis Segment
Analysis of the Ankylosing Spondylitis Segment
Segment Breakdown and Market Engineering Measurements
Patient Forecast
Pricing Trends and Forecast
Revenue Forecast
Market Share Analysis
6. The Last Word
The Last Word
Summary and Conclusions
7. Appendix
Appendix
Appendix
The United States Rheumatic Diseases Therapeutics Market published by Frost & Sullivan in August 28, 2012. This report consists of 121 Pages and the price starts from US $ 9500.
